Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ulixertinib, mk-8353, ko-947 +3 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 21 Parkinson's papers of 1,552 | 0.59 |
| pathways Reactome | 60 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 3774
Sealed predictions
- MAPK3 in dopamine neurons, braak+0.02 (p 0.964) → -0.03 (p 0.944)receipt 3782
Swarm cases
receipt 3782: MAPK3 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.800, n 18), 95% CI -0.52 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.741, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.615, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.07, sign flips 4; without severely affected donors -0.06 (p 0.800, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0075, n 18) vs -0.06 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAPK3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 5.1e-4)
Receipts
loading the receipts